Search

Your search keyword '"Picchio"' showing total 97 results

Search Constraints

Start Over You searched for: Author "Picchio" Remove constraint Author: "Picchio" Journal journal of urology Remove constraint Journal: journal of urology
97 results on '"Picchio"'

Search Results

1. PD17-07 CAN WE RELY ON AVAILABLE MODELS PREDICTING PATHOLOGICAL OUTCOMES IN PROSTATE CANCER PATIENTS STAGED WITH 68GA PSMA-PET/CT? EXTERNAL VALIDATION OF THE EXISTING NOMOGRAMS FOR EXTRACAPSULAR EXTENSION AND SEMINAL VESICLE INVASION AND DEVELOPMENT OF A NOVEL TOOL INCLUDING INTRAPROSTATIC SUVMAX

2. PD19-10 PSMA RADIO-GUIDED SURGERY TO DETECT NODAL METASTASES IN PROSTATE CANCER PATIENTS UNDERGOING ROBOT-ASSISTED RADICAL PROSTATECTOMY AND EXTENDED PELVIC LYMPH NODE DISSECTION: UPDATED RESULTS OF A PLANNED INTERIM ANALYSIS OF A PROSPECTIVE PHASE 2 STUDY

3. PD61-03 EXTERNAL VALIDATION OF THE AVAILABLE NOMOGRAMS FOR THE IDENTIFICATION OF CANDIDATES FOR a STAGING EXTENDED PELVIC LYMPH NODE DISSECTION AT THE TIME OF RADICAL PROSTATECTOMY IN PROSTATE CANCER PATIENTS PREOPERATIVELY STAGED WITH PSMA PET

4. MP14-10 IDENTIFYING THE OPTIMAL CANDIDATE FOR CONCOMITANT ANDROGEN-DEPRIVATION THERAPY AMONG PATIENTS RECEIVING METASTASIS-DIRECTED THERAPY FOR POSITIVE PSMA PET AND PRIMARY OR SECONDARY BIOCHEMICAL RECURRENCE FROM PROSTATE CANCER

5. MP14-13 EXPLORING THE INTERACTION BETWEEN THE USE OF METASTASIS DIRECTED THERAPY IN PATIENTS WITH POSITIVE PSMA PET AND PATTERNS OF BIOCHEMICAL RECURRENCE AFTER RADICAL PROSTATECTOMY. RESULTS OF A LARGE, SINGLE INSTITUTION SERIES

6. MP14-11 THE ADDED VALUE OF CONCOMITANT WHOLE-PELVIS SALVAGE RADIATION THERAPY IN OLIGO-RECURRENT PROSTATE CANCER PATIENTS TREATED WITH METASTASIS-DIRECTED THERAPY FOR DISTANT POSITIVE UPTAKES AT PSMA PET

7. MP14-01 RATES AND PREDICTORS OF FALSE NODE-POSITIVE PSMA-PET IN PATIENTS TREATED WITH RADICAL PROSTATECTOMY AND EXTEND PELVIC LYMPH-NODE DISSECTION: RESULTS FROM A LARGE, MULTI-INSTITUTIONAL DATABASE

8. MP14-04 THE ROLE OF PSA DOUBLING TIME IN THE STRATIFICATION OF PATIENTS WITH A NEGATIVE PSMA PET AFTER BIOCHEMICAL RECURRENCE OF PROSTATE CANCER: IMPLICATIONS FOR TAILORED SALVAGE TREATMENT STRATEGIES

9. MP31-19 “THE MORE YOU SEE THE MORE YOU MISS” PSMA PET/CT IS STILL AFFECTED BY A SUBSTANTIAL RISK OF UNDERESTIMATION IN PROSTATE CANCER PATIENTS UNDERGOING RADICAL PROSTATECTOMY

10. MP14-18 ONCOLOGICAL OUTCOMES OF PN1 PROSTATE CANCER PATIENTS TREATED WITH RADICAL PROSTATECTOMY: DOES MOLECULAR IMAGING HAVE A PROGNOSTIC IMPACT? RESULTS OF A LARGE, MULTI-INSTITUTIONAL SERIES

11. MP40-14 ARE EAU RISK GROUPS RELIABLE IN THE STRATIFICATION OF MEN WITH BIOCHEMICAL RECURRENCE AFTER RADICAL PROSTATECTOMY AND RESTAGED WITH PSMA-PET?

12. MP61-14 PSMA RADIO-GUIDED SURGERY TO DETECT NODAL METASTASES IN PROSTATE CANCER PATIENTS UNDERGOING ROBOT-ASSISTED RADICAL PROSTATECTOMY AND EXTENDED PELVIC LYMPH NODE DISSECTION: UPDATED RESULTS OF PLANNED INTERIM ANALYSES OF A PROSPECTIVE PHASE 2 STUDY

13. PD10-10 IMPROVING PREDICTION OF LOCAL STAGE BY PSMA-PET. DEVELOPMENT OF A NOVEL INTEGRATED TOOL FOR EXTRACAPSULAR EXTENSION AND SEMINAL VESICLE INVASION COMBINING CLINICAL AND IMAGING FEATURES IN LOCALIZED PROSTATE CANCER

14. PD10-08 THE PROGNOSTIC IMPACT OF PREOPERATIVE PSMA-PET ON EARLY ONCOLOGICAL OUTCOMES IN PROSTATE CANCER PATIENTS TREATED WITH RADICAL PROSTATECTOMY: RESULTS OF A MULTI-CENTER ANALYSIS

15. PD10-07 CAN WE RELY ON AVAILABLE MODELS TO IDENTIFY CANDIDATES FOR EXTENDED PELVIC LYMPH NODE DISSECTION (EPLND) IN MEN STAGED WITH PSMA-PET? EXTERNAL VALIDATION OF THE BRIGANTI NOMOGRAMS AND DEVELOPMENT OF A NOVEL TOOL TO IDENTIFY OPTIMAL CANDIDATES FOR EPLND

16. MP40-14 ARE EAU RISK GROUPS RELIABLE IN THE STRATIFICATION OF MEN WITH BIOCHEMICAL RECURRENCE AFTER RADICAL PROSTATECTOMY AND RESTAGED WITH PSMA-PET?

17. PD10-08 THE PROGNOSTIC IMPACT OF PREOPERATIVE PSMA-PET ON EARLY ONCOLOGICAL OUTCOMES IN PROSTATE CANCER PATIENTS TREATED WITH RADICAL PROSTATECTOMY: RESULTS OF A MULTI-CENTER ANALYSIS

18. MP61-14 PSMA RADIO-GUIDED SURGERY TO DETECT NODAL METASTASES IN PROSTATE CANCER PATIENTS UNDERGOING ROBOT-ASSISTED RADICAL PROSTATECTOMY AND EXTENDED PELVIC LYMPH NODE DISSECTION: UPDATED RESULTS OF PLANNED INTERIM ANALYSES OF A PROSPECTIVE PHASE 2 STUDY

19. PD10-10 IMPROVING PREDICTION OF LOCAL STAGE BY PSMA-PET. DEVELOPMENT OF A NOVEL INTEGRATED TOOL FOR EXTRACAPSULAR EXTENSION AND SEMINAL VESICLE INVASION COMBINING CLINICAL AND IMAGING FEATURES IN LOCALIZED PROSTATE CANCER

20. V11-02 99M-TECHNETIUM-PSMA RADIO-GUIDED SURGERY TO DETECT NODAL METASTASES IN PROSTATE CANCER PATIENTS UNDERGOING RADICAL PROSTATECTOMY AND EXTENDED PELVIC LYMPH NODE DISSECTION: A PHASE 2 PROSPECTIVE, SINGLE-INSTITUTION STUDY

21. MP51-15 THE ROLE OF 68 GA-PSMA- AND 68 GA-DOTA-RM2 PET/MRI IN THE PRIMARY STAGING OF HIGH-RISK PROSTATE CANCER PATIENTS UNDERGOING RADICAL PROSTATECTOMY. PRELIMINARY RESULTS OF A PROSPECTIVE, SINGLE CENTER STUDY

22. V11-02 99M-TECHNETIUM-PSMA RADIO-GUIDED SURGERY TO DETECT NODAL METASTASES IN PROSTATE CANCER PATIENTS UNDERGOING RADICAL PROSTATECTOMY AND EXTENDED PELVIC LYMPH NODE DISSECTION: A PHASE 2 PROSPECTIVE, SINGLE-INSTITUTION STUDY

23. MP51-15 THE ROLE OF 68 GA-PSMA- AND 68 GA-DOTA-RM2 PET/MRI IN THE PRIMARY STAGING OF HIGH-RISK PROSTATE CANCER PATIENTS UNDERGOING RADICAL PROSTATECTOMY. PRELIMINARY RESULTS OF A PROSPECTIVE, SINGLE CENTER STUDY

24. PD17-09 DEVELOPMENT OF A NOVEL RISK STRATIFICATION FOR PROSTATE CANCER PATIENTS CANDIDATE TO RADICAL PROSTATECTOMY STAGED WITH PREOPERATIVE PSMA-PET: THE KEY ROLE OF MOLECULAR IMAGING.

25. MP36-16 THE ROLE OF HISTOLOGIC SUBTYPES IN FOLLOW-UP SCHEME OF POSTSURGICAL KIDNEY CANCER PATIENTS

26. [ 11 C]Choline Positron Emission Tomography/Computerized Tomography to Restage Prostate Cancer Cases With Biochemical Failure After Radical Prostatectomy and No Disease Evidence on Conventional Imaging

27. MP36-16 THE ROLE OF HISTOLOGIC SUBTYPES IN FOLLOW-UP SCHEME OF POSTSURGICAL KIDNEY CANCER PATIENTS

28. PD11-01 COMPARISON BETWEEN THE DIAGNOSTIC ACCURACIES OF 18F-FLUORODEOXYGLUCOSE (FDG) POSITRON EMISSION TOMOGRAPHY (PET)/COMPUTED TOMOGRAPHY (CT) AND MORPHOLOGICAL IMAGING IN RECURRENT UROTHELIAL CARCINOMAS: A RETROSPECTIVE, MULTI-CENTER STUDY

29. PD38-12 [11C]CHOLINE PET/CT PREDICTS SURVIVAL IN HORMONE NAÏVE PROSTATE CANCER PATIENTS WITH BIOCHEMICAL FAILURE AFTER RADICAL PROSTATECTOMY

30. PD15-07 ASSESSING THE OPTIMAL EXTENT OF SALVAGE LYMPH NODE DISSECTION IN PATIENTS WITH SINGLE PELVIC NODAL UPTAKE AT [11C]-CHOLINE PET/CT SCAN FROM RECURRING PROSTATE CANCER

31. 178 A SINGLE SPOT AT [(11)C]CHOLINE-PET/CT SCAN IS NOT PREDICTIVE OF A SINGLE, ISOLATED NODAL METASTASIS AT FINAL PATHOLOGY. IMPLICATIONS FOR SALVAGE TREATMENTS

32. 187 IS [11C]CHOLINE PET/CT RECOMMENDED FOR RESTAGING PROSTATE CANCER PATIENTS AFTER RADICAL PROSTATECTOMY WHEN PSA IS LOWER THAN 1 NG/ML?

33. 182 EVALUATION OF LYMPH NODE RECURRENT PROSTATE CANCER WITH INTEGRATED [11C]CHOLINE PET/CT IN PATIENTS WITH PSA FAILURE AFTER RADICAL PROSTATECTOMY: VALIDATION BY HISTOLOGICAL ANALYSIS

34. 2017 FACTORS PREDICTING POSITIVE [11C]CHOLINE PET/CT IN PATIENTS WITH BIOCHEMICAL FAILURE AFTER RADICAL PROSTATECTOMY

35. PD38-12 [11C]CHOLINE PET/CT PREDICTS SURVIVAL IN HORMONE NAÏVE PROSTATE CANCER PATIENTS WITH BIOCHEMICAL FAILURE AFTER RADICAL PROSTATECTOMY

36. PD15-07 ASSESSING THE OPTIMAL EXTENT OF SALVAGE LYMPH NODE DISSECTION IN PATIENTS WITH SINGLE PELVIC NODAL UPTAKE AT [11C]-CHOLINE PET/CT SCAN FROM RECURRING PROSTATE CANCER

38. 182 EVALUATION OF LYMPH NODE RECURRENT PROSTATE CANCER WITH INTEGRATED [11C]CHOLINE PET/CT IN PATIENTS WITH PSA FAILURE AFTER RADICAL PROSTATECTOMY: VALIDATION BY HISTOLOGICAL ANALYSIS

39. 187 IS [11C]CHOLINE PET/CT RECOMMENDED FOR RESTAGING PROSTATE CANCER PATIENTS AFTER RADICAL PROSTATECTOMY WHEN PSA IS LOWER THAN 1 NG/ML?

40. 178 A SINGLE SPOT AT [(11)C]CHOLINE-PET/CT SCAN IS NOT PREDICTIVE OF A SINGLE, ISOLATED NODAL METASTASIS AT FINAL PATHOLOGY. IMPLICATIONS FOR SALVAGE TREATMENTS

42. VALIDATION OF THE CRITERIA SUGGESTED BY CURRENT GUIDELINES TO INDICATE THE NEED FOR BASELINE STAGING BONE SCAN IN PATIENTS WITH NEWLY DIAGNOSED PROSTATE CANCER

43. DETECTION OF LYMPH-NODE METASTASES WITH INTEGRATED [11C]CHOLINE PET/CT IN PATIENTS WITH PSA FAILURE AFTER RADICAL RETROPUBIC PROSTATECTOMY: VALIDATION BY OPEN PELVIC-RETROPERITONEAL LYMPHADENECTOMY

44. A NOVEL NOMOGRAM PREDICTING A POSITIVE [ 11 C]CHOLINE POSITRON EMISSION TOMOGRAPHY/COMPUTED TOMOGRAPHY (PET/TC) SCAN IN PATIENTS WITH BIOCHEMICAL RECURRENCE AFTER RADICAL PROSTATECTOMY

45. A NOVEL NOMOGRAM PREDICTING A POSITIVE [ 11 C]CHOLINE POSITRON EMISSION TOMOGRAPHY/COMPUTED TOMOGRAPHY (PET/TC) SCAN IN PATIENTS WITH BIOCHEMICAL RECURRENCE AFTER RADICAL PROSTATECTOMY

46. VALIDATION OF THE CRITERIA SUGGESTED BY CURRENT GUIDELINES TO INDICATE THE NEED FOR BASELINE STAGING BONE SCAN IN PATIENTS WITH NEWLY DIAGNOSED PROSTATE CANCER

48. 1555: The Role of Integrated 11C-Choline Pet/CT Scan in Re-Staging Patients with Biochemical Failure after Radical Retropubic Prostatectomy: Hystologic Correlations after Pelvic or Retroperitoneal Lympho-Node Dissection

49. 1555: The Role of Integrated 11C-Choline Pet/CT Scan in Re-Staging Patients with Biochemical Failure after Radical Retropubic Prostatectomy: Hystologic Correlations after Pelvic or Retroperitoneal Lympho-Node Dissection

50. Value of [ 11 C]choline-Positron Emission Tomography for Re-Staging Prostate Cancer: A Comparison With [ 18 F]fluorodeoxyglucose-Positron Emission Tomography

Catalog

Books, media, physical & digital resources